Second US Clinical Study In HIV/AIDS Lymphoma Patients Using Benitec Limited (BLT.AX) ddRNAi Technology
3/21/2011 10:25:26 AM
Sydney, Mar 21, 2011 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in RNA-based gene silencing for human therapeutics, is pleased to acknowledge that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec's DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.
comments powered by